Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Neoplasm Metastasis 40Lung Neoplasms 32Multiple Myeloma 24Leukemia, Myeloid, Acute 24Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Breast Neoplasms 19Urinary Bladder Neoplasms 17Pancreatic Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Melanoma 14Carcinoma, Renal Cell 12Sarcoma 11Glioma 11Carcinoma, Transitional Cell 11Mouth Neoplasms 10Fallopian Tube Neoplasms 10Endometrial Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neuroblastoma 9Laryngeal Neoplasms 9Glioblastoma 9Carcinoma 9Burkitt Lymphoma 9Stomach Neoplasms 8Oropharyngeal Neoplasms 8Osteosarcoma 7

Interventions

Cytarabine 13fludarabine phosphate 8Etoposide 8Methotrexate 7Idarubicin 6Daunorubicin 6Busulfan 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Vorinostat 4Tacrolimus 4Mitoxantrone 4Cyclophosphamide 4Azacitidine 4Antilymphocyte Serum 4merphos 3Topotecan 3Thioguanine 3Cyclosporine 3sargramostim 2laromustine 2Specimen Handling 2Radiotherapy 2Methylprednisolone 2Lenalidomide 2Hydrocortisone 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Anemia, Refractory, with Excess of Blasts × Specimen Handling × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡